Free Trial

Quest Diagnostics (DGX) Stock Price, News & Analysis

-0.83 (-0.58%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
561,664 shs
Average Volume
1.03 million shs
Market Capitalization
$15.92 billion
P/E Ratio
Dividend Yield
Price Target

Quest Diagnostics MarketRank™ Stock Analysis

Analyst Rating
2.25 Rating Score
2.0% Upside
$146.17 Price Target
Short Interest
2.53% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.36mentions of Quest Diagnostics in the last 14 days
Based on 29 Articles This Week
Insider Trading
Selling Shares
$2.16 M Sold Last Quarter
Proj. Earnings Growth
From $8.78 to $9.44 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

19th out of 922 stocks

Medical Laboratories Industry

2nd out of 18 stocks

DGX stock logo

About Quest Diagnostics Stock (NYSE:DGX)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

DGX Stock Price History

DGX Stock News Headlines

Lab Week 2024 - Deepika Kumar
More Workers Are Cheating on Drug Tests
Cheating on Workplace Drug Tests Hits a Record
Lab Week 2024 - Javarus Smith
Quest Diagnostics: Let's Keep Waiting
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
See More Headlines
Receive DGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 4/22 Dividend
Dividend Payable
Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Health Care Services
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
$854 million
Pretax Margin


Sales & Book Value

Annual Sales
$9.25 billion
Cash Flow
$12.66 per share
Book Value
$56.41 per share


Free Float
Market Cap
$15.91 billion

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

DGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quest Diagnostics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DGX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DGX, but not buy additional shares or sell existing shares.
View DGX analyst ratings
or view top-rated stocks.

What is Quest Diagnostics' stock price target for 2024?

12 brokerages have issued 1 year price objectives for Quest Diagnostics' stock. Their DGX share price targets range from $130.00 to $160.00. On average, they anticipate the company's stock price to reach $146.17 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price.
View analysts price targets for DGX
or view top-rated stocks among Wall Street analysts.

How have DGX shares performed in 2024?

Quest Diagnostics' stock was trading at $137.88 on January 1st, 2024. Since then, DGX shares have increased by 4.0% and is now trading at $143.34.
View the best growth stocks for 2024 here

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a drop in short interest in April. As of April 30th, there was short interest totaling 2,800,000 shares, a drop of 7.3% from the April 15th total of 3,020,000 shares. Based on an average daily trading volume, of 981,200 shares, the short-interest ratio is currently 2.9 days. Currently, 2.5% of the shares of the stock are sold short.
View Quest Diagnostics' Short Interest

When is Quest Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024.
View our DGX earnings forecast

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Incorporated (NYSE:DGX) released its earnings results on Tuesday, April, 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.86 by $0.18. The medical research company earned $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a trailing twelve-month return on equity of 15.52%. The business's quarterly revenue was up 1.7% compared to the same quarter last year. During the same period last year, the business earned $2.04 earnings per share.
Read the conference call transcript

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Wednesday, May 15th. Shareholders of record on Monday, July 8th will be paid a dividend of $0.75 per share on Monday, July 22nd. This represents a $3.00 dividend on an annualized basis and a yield of 2.09%. The ex-dividend date of this dividend is Monday, July 8th.
Read our dividend analysis for DGX

Is Quest Diagnostics a good dividend stock?

Quest Diagnostics (NYSE:DGX) pays an annual dividend of $2.84 per share and currently has a dividend yield of 1.97%. The company has been increasing its dividend for 13 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 38.22%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DGX will have a dividend payout ratio of 30.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DGX.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its board has initiated a share repurchase program on Thursday, February 2nd 2023, which allows the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics issued an update on its FY 2024 earnings guidance on Tuesday, April, 23rd. The company provided earnings per share (EPS) guidance of 8.720-8.970 for the period, compared to the consensus EPS estimate of 8.750. The company issued revenue guidance of $9.4 billion-$9.5 billion, compared to the consensus revenue estimate of $9.4 billion.

What is Steve Rusckowski's approval rating as Quest Diagnostics' CEO?

1,053 employees have rated Quest Diagnostics Chief Executive Officer Steve Rusckowski on Steve Rusckowski has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), Abbott Laboratories (ABT), NVIDIA (NVDA), Intel (INTC) and Cisco Systems (CSCO).

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (12.53%), Nuance Investments LLC (0.61%), Bessemer Group Inc. (0.59%), Nordea Investment Management AB (0.54%), BNP Paribas Financial Markets (0.47%) and CANADA LIFE ASSURANCE Co (0.37%). Insiders that own company stock include Catherine T Doherty, Gail R Wilensky, Karthik Kuppusamy, Michael E Prevoznik, Michael J Deppe, Stephen H Rusckowski, Stephen H Rusckowski, Timothy M Ring and Vicky B Gregg.
View institutional ownership trends

How do I buy shares of Quest Diagnostics?

Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Quest Diagnostics have any subsidiaries?
The following companies are subsidiares of Quest Diagnostics: AmeriPath, AmeriPath Cincinnati Inc. (OH), AmeriPath Cleveland Inc. (OH), AmeriPath Consolidated Labs Inc. (FL), AmeriPath Florida LLC (DE), AmeriPath Hospital Services Florida LLC (DE), AmeriPath Inc. (DE), AmeriPath Indianapolis PC (IN), AmeriPath Kentucky Inc. (KY), AmeriPath Lubbock 5.01(A) Corporation (TX), AmeriPath New York LLC (DE), AmeriPath Texas Inc. (DE), AmeriPath Tucson Inc. (AZ), American Medical Laboratories, American Medical Laboratories Incorporated (DE), Associated Clinical Laboratories L.P. (PA), Associated Clinical Laboratories of Pennsylvania L.L.C. (PA), Athena Diagnostics, Athena Diagnostics Inc. (DE), Blueprint Genetics, Blueprint Genetics FZ-LLC (UAE), Blueprint Genetics Inc. (DE), Blueprint Genetics Oy (Finland), California Laboratory Associates, Cape Cod Healthcare - Business, Celera, ClearPoint Diagnostic, Clearpoint Diagnostic Laboratories LLC (TX), Cleveland HeartLab, Cleveland HeartLab Inc. (DE), Clinical Laboratory Partners, Colorado Pathology Consultants P.C. (CO), ConVerge Diagnostic Services, Consolidated DermPath Inc. (DE), DFW 5.01(a) Corporation (TX), DGXWMT JV LLC (DE), Dermatopathology of Wisconsin S.C. (WI), Diagnostic Laboratory of Oklahoma LLC (OK), Diagnostic Pathology Services Inc. (OK), Diagnostic Reference Services Inc. (MD), ExamOne Canada Inc. (New Brunswick), ExamOne LLC (DE), ExamOne World Wide Inc. (PA), ExamOne World Wide of NJ Inc. (NJ), Focus Diagnostics, HemoCue, Hoffman M.D. Associated Pathologists Chartered (NV), Institute for Dermatopathology Inc. (PA), Isabella Street Urban Renewal LLC (NJ), Kailash B. Sharma M.D. Inc. (GA), Kilpatrick Pathology P.A. (NC), LabOne, LabOne LLC (MO), LabOne of Ohio Inc. (DE), Laboratorio de Analisis Biomedicos S.A. (Mexico), Lancet Labs, MACL, Med Fusion LLC (TX), Med fusion, MedPlus, Mid America Clinical Laboratories LLC (IN), Nomad Massachusetts Inc. (MA), Nuclear Medicine and Pathology Associates (GA), Ocmulgee Medical Pathology Association Inc. (GA), Pathology Building Partnership (MD) (gen. ptnrshp.), PeaceHealth Laboratories, PhenoPath Laboratories, PhenoPath Laboratories PLLC (WA), Q Squared Solutions Holdings LLC (DE), Q Squared Solutions Holdings Limited (UK), Quest Diagnostics (Shanghai) Co. Ltd. (China), Quest Diagnostics Brasil Holdings Ltd. (UK), Quest Diagnostics Clinical Laboratories, Quest Diagnostics Clinical Laboratories Inc. (DE), Quest Diagnostics Domestic Holder LLC (DE), Quest Diagnostics HTAS India Private Limited (India), Quest Diagnostics Health & Wellness LLC (DE), Quest Diagnostics Holdings Incorporated (DE), Quest Diagnostics Holdings Ltd. (UK), Quest Diagnostics Incorporated (MD), Quest Diagnostics Incorporated (NV), Quest Diagnostics India Private Limited (India), Quest Diagnostics Infectious Disease Inc. (DE), Quest Diagnostics International Holdings Limited (UK), Quest Diagnostics International LLC (DE), Quest Diagnostics Investments LLC (DE), Quest Diagnostics Ireland Limited (Ireland), Quest Diagnostics LLC (CT), Quest Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Massachusetts LLC (MA), Quest Diagnostics Mexico Holding Company Trust (Mexico), Quest Diagnostics Mexico S de RL de CV (Mexico), Quest Diagnostics Nichols Institute (CA), Quest Diagnostics Nichols Institute Inc. (VA), Quest Diagnostics Receivables Inc. (DE), Quest Diagnostics Subsidiary Holdings Ltd. (UK), Quest Diagnostics TB LLC (DE), Quest Diagnostics Terracotta LLC (DE), Quest Diagnostics Venture LLC (PA), Quest Diagnostics Ventures LLC (DE), Quest Diagnostics do Brasil Ltda. (Brazil), Quest Diagnostics of Pennsylvania Inc. (DE), Quest Diagnostics of Puerto Rico Inc. (PR), Quest HealthConnect LLC (CA), ReproSource, Reprosource Fertility Diagnostics Inc. (MA), Solstas Lab Partners, Sonora Quest Laboratories LLC (AZ), Specialty Laboratories Inc. (CA), Summit Health, UMass Memorial Medical Center - Anatomic Pathology Outreach Laboratory Business, Unilab Corporation, and Unilab Corporation (DE).
Read More
This page (NYSE:DGX) was last updated on 5/21/2024 by Staff

From Our Partners